Moreover, due to the acquired tolerance of first-generation EGFR-TKI, many NSCLC patients need to take third-generation EGFR-TKI instead, and the impact of such sequential medication on QT interval is also unelucidated. This evidence concerns the gene EGFR and non-small cell lung carcinoma.